Majesale Biotechnology

Majesale Biotechnology is an early-stage biopharmaceutical company focused on the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company leverages its expertise in immunology to target key pathways such as the IL-17/IL-23 axis and JAK/TYK signaling. Majesale's current efforts are centered on developing high-potency small molecules and biologics designed to provide superior efficacy and safety profiles for patients with chronic inflammatory conditions. The company is primarily operating in the pre-clinical research phase, establishing a pipeline of candidates for dermatological and rheumatological indications.